Informed Choice Washington

Pertussis (Whooping Cough)

References cited in the video Herd Immunity: Whooping Cough

  1. PMID: 15304469 Association between carriage of Streptococcus pneumoniae and Staphylococcus aureus in Children.
  2. PMID: 18270917 Pneumococcal vaccination: conjugated vaccine induces herd immunity and reduces antibiotic resistance
  3. PMID: 7898220 Increase in pneumococcal bacteraemia in Sweden.
  4. PMID: 15361720 Changes in frequency and pathogens causing acute otitis media in 1995-2003.
  5. PMID: 15937758 Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups
  6. ScienceDaily, January 28, 2011, “How bacteria keep ahead of vaccines and antibiotics.”
  7. PMID: 15304469 Association between carriage of Streptococcus pneumoniae and Staphylococcus aureus in Children.
  8. Janeway’s Immunobiology
  9. www.CDC.gov
  10. PMID: 28289058 What Is Wrong with Pertussis Vaccine Immunity? Inducing and Recalling Vaccine-Specific Immunity.
  11. PMID: 28289059 What Is Wrong with Pertussis Vaccine Immunity? Why Immunological Memory to Pertussis Is Failing.
  12. PMID: 28289064 What Is Wrong with Pertussis Vaccine Immunity? The Problem of Waning Effectiveness of Pertussis Vaccines.
  13. PMID: 24443545 Different effects of whole-cell and acellular vaccines on Bordetella transmission.
  14. PMID: 24277828 Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model.
  15. PMID: 10463173 Antigenic variants in Bordetella pertussis strains isolated from vaccinated and unvaccinated children.
  16. PMID: 19579693 A natural pertactin deficient strain of Bordetella pertussis shows improved entry in human monocyte-derived dendritic cells.
  17. PMID: 22914363 Appearance of Bordetella pertussis strains not expressing the vaccine antigen pertactin in Finland.
  18. PMID: 19751581 Bordetella pertussis strains with increased toxin production associated with pertussis resurgence.
  19. PMID: 24216286 Pertussis epidemic despite high levels of vaccination coverage with acellular pertussis vaccine.
  20. PMID: 24655754 A rapid ELISA-based method for screening Bordetella pertussis strain production of antigens included in current acellular pertussis vaccines.
  21. PMID: 28076445 Emerging Bordetella pertussis Strains Induce Enhanced Signaling of Human Pattern Recognition Receptors TLR2, NOD2 and Secretion of IL-10 by Dendritic Cells
  22. PMID: 24277828 Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model.
  23. INFECTIOUS BEHAVIOR: Brain Immune Connections in Autism, Schizophrenia, and Depression by Dr. Paul H. Patterson
  24. PMID: 28188123 The Introduction of Diphtheria-Tetanus-Pertussis and Oral Polio Vaccine Among Young Infants in an Urban African Community: A Natural Experiment.
  25. EVERY SECOND CHILD by Dr. Archie Kalokerinos
  26. PMID: 24325827 Co-administration of live measles and yellow fever vaccines and inactivated pentavalent vaccines is associated with increased mortality compared with measles and yellow fever vaccines only. An observational study from Guinea-Bissau.
  27. PMID: 21691704 In vivo study of hepatitis B vaccine effects on inflammation and metabolism gene expression.
  28. PMID: 15626943 Hepatitis B vaccination associated with higher female than male mortality in Guinea-bissau: an observational study.
  29. PMID: 7975851 Suboptimal response following intradermal hepatitis B vaccine in infants.
  30. PMID: 24570246 Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections.
  31. PMID: 27840013 Simultaneous Vaccination with MMR and DTaP-IPV-Hib and rate of hospital admissions with any infections: A nationwide register based cohort study
  32. Federal Register, DHHS, FDA 1984, Vol. 49, No. 107

Vaccination does not prevent transmission

Pertussis is a very serious infection and vaccination does not prevent either colonization or transmission. In fact recent studies have shown that when exposed to pertussis (whooping cough) those who are vaccinated with the acellular pertussis vaccine are as contagious as those who are not vaccinated, only without warning symptoms to let them know they are contagious.

“Meanwhile, there was no difference in either the duration or in B. pertussis burden between unvaccinated and acellular-pertussis-vaccinated animals, while previously infected animals were not colonized following reinfection.”

Warfel JM, Zimmerman LI, Merkel TJ. 2016. Comparison of three whole-cell pertussis vaccines in the baboon model of pertussis. Clin Vaccine Immunol 23:47–54. doi:10.1128/CVI.00449-15.

A couple facts important to know:

  • While pertussis is very serious, in Washington State, there were only 4 Pertussis deaths in 21 years from 1959 to 1980.
  • In the 1990’s, because DTP came with such high risk of injury, it was replaced in the U.S. with the acellular (not live) DTaP and Tdap vaccines. Although capable of providing limited personal protection, these vaccines also come with risks, the protection wanes quickly, they don’t protect against mutant and emerging strains, and they cannot prevent the colonization or transmission of infection.
  • Large outbreaks are occurring in fully vaccinated populations to those who have received multiple vaccine doses. Studies are showing that repeated vaccination decreases the ability to fight the infection, and mutant strains now make up 90% of pertussis infections in western countries. See the video at the top of this page – Herd Immunity: Whooping Cough by Dr. Suzanne Humphries.
  • Repeated vaccination leads to the danger of hyperimmunization. This is of particular concern for the tetanus vaccine.  See PMID 3499712, 8491525, 22235053, 22875539, 23238161, 25430703.
  • Because of a phenomenon known as “original antigenic sin,” each subsequent vaccination with acellular pertussis vaccine makes the immune system more vaccine-strain-specific and less able to bind with wild pertussis. Lengthier infection times in those who are asymptomatic also leads to more virus mutations for which the vaccine is not protective.
  • It’s important to know how to recognize potential pertussis infections, how the infection progresses, what symptoms mean, and treatment options. Always consult with your trusted medical advisor.

The science on pertussis vaccines is far from settled. Public health messages claim them to be “safe and effective” and yet scientists know that the available vaccines, the diseases they aim to prevent, and the human immune system are not yet fully understood. The below abstract is from the June 2017 paper: Pertussis disease and transmission and host responses: insights from the baboon model of pertussis. https://www.ncbi.nlm.nih.gov/pubmed/28646950

Abstract

Whooping cough is a highly contagious, acute respiratory disease, caused by the Gram-negative bacterium Bordetella pertussis (Bp). Despite the introduction and widespread use of vaccines starting in the 1950s pertussis cases continue to be reported, with a significant global impact. The role of specific virulence factors in disease and the immune mechanisms associated with protection following natural infection or vaccination are still not completely understood. 

During any whooping cough outbreak, government and medical agencies and the media put out messages for the community to get vaccinated. This advice provides some level of personal protection (about 70% effective against Bordetella pertussis but may be ineffective against Bordetella parapertussis) for a limited time (2-5 years is the latest guess)–but that means perhaps 30% of those vaccinated are not protected, 70% are potentially asymptomatic vectors, and waning protection in fully vaccinated populations or households means many are susceptible to infection.

Image from FDA: Modeling Pertussis Disease and Transmission

 

Because this information is not commonly known, there is a false sense of security. Proper precautions are not being taken around newborns or the immunocompromised. Cocooning is potentially hazardous. It is a dilemma the scientific community is working hard to fix.

Image from FDA: Modeling Pertussis Disease and Transmission

The CDC advises the screening of potential typical carriers during outbreaks — but such advice is insufficient to contain any outbreak. Everyone potentially exposed to pertussis needs to be tested whether or not there are symptoms present. This might seem unfeasible now, but new diagnostic technology has been developed that may make testing cost effective and fast. The developing field of RDT (rapid diagnosis technology) for pertussis and other communicable infections may provide essential tools that can be incorporated into public health measures to help limit the spread of infection.

http://www.hain-lifescience.de/en/products/microbiology/bordetella/genoquick-bordetella.html

Vaccination during pregnancy does not guarantee protection nor has it been proven safe. The FDA baboon studies found that it was possible to generate antibodies in the infant by maternal and early neonatal vaccination that proved effective in reducing or eliminating symptoms of infection when challenged, but the young baboons still colonized and transmitted infection, and the study design could not speak to safety for the human fetus or child, nor the impact of repeated vaccinations with each pregnancy, nor the long-term impact on neurological or immune health.

The FDA has not approved the pertussis vaccine–nor any vaccine–for use during pregnancy for specific protection of the infant because adequate safety studies have not been done.

“Several licensed vaccines may be used during pregnancy to prevent disease in the mother, unless specifically contraindicated, Tdap & Influenza. Vaccines recommended for pregnant women were first licensed and approved for use based on safety and effectiveness data in non-pregnant women. These vaccines were then recommended by public health policy makers for pregnant women based on their perceived benefit and minimal risk for the mother and infant. Currently, no vaccine is approved specifically for use during pregnancy to protect the infant.

https://www.fda.gov/downloads/AboutFDA/Transparency/Basics/UCM509197.pdf

The FDA will not approve vaccines for pregnant women for protection of the infant until the appropriate studies are done, but it is repeatedly said it is unethical to run clinical trials with pregnant women because it could put the fetus in jeopardy. So why is it ethical to recommend these vaccines to pregnant women in the general population?

Pregnant women are being told that they are being given vaccines to protect the baby in language that implies, if not outright states, that appropriate safety studies have been done. They have not. Pregnant women in the general population are in essence being used in ongoing clinical trials without their fully informed consent.

Over the years, data has been gathered in a haphazard fashion using voluntary registries set up by pharmaceutical companies and in adverse event reports to VAERS, both of which suffer from extreme under-reporting. VSD (Vaccine Safety Datalink) studies on the safety of vaccination during pregnancy mostly include only pregnancies with live-birth outcomes, and very few studies look at the long-term health effects on children. One such rare study on vaccination with the influenza vaccine during pregnancy (Zerbo et al) found a significant association with autism. Even the most elaborate and inappropriate application of adjustments and corrections could not make the association go away in the first trimester, so the authors simply dismissed the result as due to chance. This is not science. http://jamanetwork.com/journals/jamapediatrics/article-abstract/2617988

The impact of maternal immune activation during pregnancy, and the impact of exposure to various vaccine components, such as the placenta-crossing 250 mcg of aluminum in the Tdap, on long-term neurological development are not known, but there’s enough science indicating that extreme caution is warranted. The current push to vaccinate during every single pregnancy, as well as during every outbreak, comes without any understanding of the health effect of such frequent administration of three disease antigens (tetanus, diphtheria, pertussis) and other vaccine components. This is a small sampling of studies on one component, aluminum:

Pertussis is a very serious infection. Vaccination comes with risk, provides limited protection, and creates asymptomatic carriers. Safety during pregnancy has not been established. Outbreaks will continue to occur, and it’s critical that everyone be sufficiently informed of vaccination limitations and risks in order to behave in as safe a manner as possible around vulnerable populations.

Additionally, other tools must be utilized to detect those who are infected, and the safest most effective healing approaches explored in order to improve outcomes of those who become infected. It is becoming increasingly clear that pertussis is not an ideal candidate for control or eradication by vaccination.

  • What Is Wrong with Pertussis Vaccine Immunity? The Problem of Waning Effectiveness of Pertussis Vaccines. PMID: 28289064

Global, federal, and state initiatives and incentives are creating enormous pressure to increase vaccination levels. None of these programs have written into their description any regard for the limitations and risks of vaccination, individual genetic or environmental susceptibility, the flexibility to incorporate new science into the plan, or any regard for medical freedom of choice. It is an undeniable fact that the entire population cannot be safely vaccinated, but protection of those at risk of injury or death from vaccination is not built into any of the programs. And in the absence of anyone being responsible for vaccine injury–from those who make vaccines, to those who administer vaccines, to health departments that promote vaccines–the messages being conveyed to the public never contain vaccine limitation and risk information critical to protecting individual health.

Science of the Dtap/Tdap/aP Vaccine

More Studies

  • Pertussis carrier: http://www.fda.gov/…/Newsr…/PressAnnouncements/ucm376937.htm
  • Diphtheria carrier: http://www.cdc.gov/diphtheria/clinicians.html
  • Pertussis epidemic despite high levels of vaccination coverage with acellular pertussis vaccine. http://www.ncbi.nlm.nih.gov/m/pubmed/24216286/
  • “Further, we show that aP vaccination impedes host immunity against B. parapertussis-measured as reduced lung inflammatory and neutrophil responses. Thus, we conclude that aP vaccination interferes with the optimal clearance of B. parapertussis and enhances the performance of this pathogen. Our data raise the possibility that widespread aP vaccination can create hosts more susceptible to B. parapertussis infection.” http://www.ncbi.nlm.nih.gov/m/pubmed/20200027/
  • “Our unvaccinated and under-vaccinated population did not appear to contribute significantly to the increased rate of clinical pertussis. Surprisingly, the highest incidence of disease was among previously vaccinated children in the eight to twelve year age group.” http://www.ncbi.nlm.nih.gov/pubmed/22423127
  • Vaccinations create more powerful and virulent strains of bacteria and viruses. The reason for the current whooping cough outbreak. Read more here from the CDC “Vaccination against 2 avian viruses, the Marek disease virus, and the infectious bursal disease virus, were associated with the emergence of more virulent strains (33). An important role of host immunity in selecting for virulence is also suggested by the co-evolution of the myxomatosis virus and rabbits (34). Furthermore, immune pressure was shown to select for more virulent Plasmodium chabaudi parasites in mice (35). Based on mathematical modeling, vaccines designed to reduce pathogen growth rate and/or toxicity may result in the evolution of pathogens with higher levels of virulence. http://wwwnc.cdc.gov/eid/article/15/8/08-1511_article.htm
  • “After the fifth dose of DTaP, the odds of acquiring pertussis increased by an average of 42% per year.” http://www.nejm.org/doi/full/10.1056/NEJMoa1200850…
  • This study shows that efficacy of the DTaP falls rapidly. At 2 years post-vaccination, it’s just 75%. By 5 years, it’s down to 11.9%. http://www.ncbi.nlm.nih.gov/pubmed/24903664
  • Pertussis 53 – 64% effective in adolescents and adults: http://www.ncbi.nlm.nih.gov/pubmed/23873919
  • Tetanus is anaerobic, so it dies when it hits oxygen. Bleeding from an injury is a good thing. Tetanus is more common where farm animal feces is present. If tetanus is suspected, an immune globulin shot can be administered. Getting a tetanus shot at the time of injury is a moot point. It would take several weeks to create antibodies, and if tetanus were present, death could occur within a week. Tetanus is extremely rare. Severe tetanus in immunized patients with high anti-tetanus titers. https://www.ncbi.nlm.nih.gov/m/pubmed/1565228/
  • Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines in pregnant women. https://www.ncbi.nlm.nih.gov/m/pubmed/22727350/

Risks of Dtap/TDap (beyond vaccine failure)

  • The Dtap/TDap vaccine is associated with the most adverse reactions recorded (VAERS database.)
  • See Aluminum and Mitochondria pages
  • this section under construction

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save